InvestorsHub Logo

BRoberts1982

06/17/17 11:30 AM

#37006 RE: Drugdoctor #37004

OK NEXT, a GBSN history

Date Reverse Split Ratio

March 31, 2016 35 to 1
September 16, 2016 80 to 1
December 28, 2016 300 to 1
April 10, 2017 2,000 to 1
Cumulative Ratio 1,680,000,000 to 1
(This ONLY accounts for 4 of the 5 reverse splits)

Our near-term success is dependent upon our ability to expand our customer base.
As of March 31, 2017, we had 235 in the United States.
(That is down from 260 last year)

We have not generated profits and do not expect to generate profits for the foreseeable future. We may never achieve or sustain profitability.
Loss from operations
2016 (34,080,946)
2015 (22,405,796)

We began operations in January 2005. We have NOT earned significant revenue to-date, and do not expect to earn significant revenue in the near future.

As of March 31, 2017, December 31, 2016, and December 31, 2015, we had an accumulated deficit of $189.6 million, $211.1 million and $121.9 million

Total compensation of the executives for the last couple years:
(They gave themselves nice bonuses in 2015 for such fine work)

Ryan Ashton
President, Chief Executive Officer and Director
2016 441,153
2015 694,654

Robert Jenison Chief Technology Officer
2016 273,210
2015 346,072

Jeffrey Rona Chief Financial Officer
2016 348,210
2015 443,572

The following are the compensatory arrangements for our non-employee directors:

Director Position Annual Payment
Executive Chairman Retainer $ 180,000
Director Retainer paid to all directors $ 35,000
Lead Director Supplement $ 35,000
Audit Committee Chair $ 10,000
Audit Committee Member $ 5,000
Compensation Committee Chair $ 10,000

Total liabilities
2016 $129,383,630
2015 $51,753,326

Total liabilities and stockholders’ deficit
2016 $73,397,337
2015 $28,558,363


.......NEXT